Table 2.
Medical care for allergic rhinitis.
Characteristics | Analysed population N = 1929 |
|
---|---|---|
AR follow-up | First consultation for AR | 34.3% |
Regular follow-up by GP | 57.4% | |
Regular follow-up by an allergy specialist | 2.0% | |
At least one consultation with an allergy specialist | 36.9% | |
Unknown care course | 6.2% | |
Main consultation reason | Immediate release | 56.6% |
Treatment renewal | 35.1% | |
Prescription of long-term treatment | 30.7% | |
Change/adjustment of ongoing treatment | 16.4% | |
Ongoing symptomatic treatment | At least one | 64.6% |
Oral anti-H1 | 59.9% | |
Intranasal steroids | 27.6% | |
Intranasal anti-H1 | 14.1% | |
Intraocular cromone | 11.0% | |
Intraocular anti-H1 | 10.2% | |
1/2/3/>3 therapies | 19.6%/22.5%/17.8%/4.6% | |
Self-medication | 15.7% | |
Prescribed symptomatic treatment | At least one | 99.5% |
Oral anti-H1 | 97.7% | |
Intranasal steroids | 47.8% | |
Intranasal anti-H1 | 24.7% | |
Intraocular cromone | 21.7% | |
Intraocular anti-H1 | 19.5% | |
1/2/3/>3 therapies | 20.1%/34.2%/35.0%/10.7% | |
Allergen immunotherapy | Yes, whenever | 7.4% |
Yes, ongoing | 2.2% | |
Against: | ||
Mites | 5.9% | |
Grass pollen | 5.7% | |
Tree pollens | 2.7% | |
Herbaceous pollen | 1.8% | |
Animal dander | 1.6% | |
Fungal spores | 0.9% | |
Other | 0.4% | |
Referred to a specialist | Yes: | 15.1% |
Allergy specialist | 12.2% | |
Lung specialist | 2.8% | |
ENT specialist | 2.6% | |
Dermatologist | 0.7% | |
Sick leave prescription | Yes | 1.6% |
Duration (if yes) | 4.8 ± 2.7 days |
Values are mean ± standard deviation for continuous variables, and % of classes for categorical variables.